Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($0.86) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

Several other research analysts also recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Price Performance

NASDAQ RGLS opened at $1.50 on Monday. The stock has a market capitalization of $98.25 million, a P/E ratio of -1.40 and a beta of 1.63. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The business has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $1.81.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Equities analysts expect that Regulus Therapeutics will post -0.83 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of Regulus Therapeutics during the 3rd quarter valued at about $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Victory Capital Management Inc. raised its holdings in Regulus Therapeutics by 10.4% during the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after acquiring an additional 37,480 shares during the period. Renaissance Technologies LLC lifted its holdings in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Regulus Therapeutics in the 2nd quarter worth approximately $136,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.